Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nous-PEV with Pembrolizumab in Advanced Melanoma and NSCLC
NCT04990479Phase 1Terminated
- Sponsor
- Nouscom
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Viral Vectors, Cancer Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of NOUS-PEV in cutaneous melanoma (CM) and non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Nouscom. Primary endpoint: Incidence of treatment-emerging adverse events up to 110 weeks. Started Jun 2021; status: terminated.
02
Drugs
NOUS-PEV
03
Conditions
cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04990479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990479.